Skip to Content
scroll

PYC Therapeutics Ltd (PYC)

ASX.PYC $0.11

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

LEARN MORE

PYC $0.11

20 MINUTE DELAYED

TODAY

-2.27 %

1 YEAR RETURN

0.00%

VOLUME

314,494

DIV YIELD

0%

PE RATIO

0.00

52 WEEK RANGE

0.05

0.14

ANALYSIS

i

SHARE PRICE ACTIVITY
Last (Price)

0.11

Change

0.00 (-2.27)

Bid / Ask

0.11 - 0.11

Volume

314,494

Turnover

34,494

Open

0.11

Day Range

0.11 - 0.11

VWAP

0.11

Prev Close

0.11

Last Trade

24/07 3:30pm (AEST)

i

KEY INFORMATION
Sector

Shares Issued

NTA/Share

0.00

Last Dividend

0.00

Dividend Ex Date

0

Dividend Pay Date

29 MAR 2006

i

BROKER CALLS

current

Mean

2.00

Target Price

0.00

BUY

i

CURRENT ()
Revenue

15.91

EBITDA

-22.80

Profit

-22.79

Earnings Per Share (EPS)

0

Dividend Per Share (DPS)

0

Yield %

0.00

Market Cap

0

Price to Earnings Ratio (P/E)

0

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

6.28

EBITDA

-36.05

Profit

-33.89

Earnings Per Share (EPS)

-0.01

Dividend Per Share (DPS)

0.00

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation (BUY)

2.00
image description

Business Summary

PYC Therapeutics Limited is an Australia-based pre-clinical-stage biotechnology company, which offers ribonucleic acid (RNA) therapeutics to meet unmet needs in disease. The Company has RNA targeted therapeutics design capabilities to deliver technologies based on cell penetrating peptides (CPPs) and peptide conjugated phosphorodiamidate morpholino oligomer (PPMOs). The Company develops a pipeline of therapies, including two programs, which are focused on inherited eye diseases and preclinical discovery programs, which are focused on neurodegenerative and kidney diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA). Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The Company's discovery and laboratory operations are located in Australia.

image description

Relevant suggested news and content from the site

image description

Only available to Members

Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing. Click here
Back to top